Risk factors for Pneumocystis jiroveci pneumonia (PcP) in renal transplant recipients

Nephrology Dialysis Transplantation

Volumn 26, Issue 6, 2011, Pages 2013-2017

  Eitner, Frank ^a   Hauser, Ingeborg A ^b   Rettkowski, Olaf ^c   Rath, Thomas ^d   Lopau, Kai ^c   Pliquett, Rainer U ^b   Fiedler, Roman ^c   Guba, Markus ^e   Hilgers, Ralf Dieter ^a   Floege, Jrgen ^a   Fischereder, Michael ^e  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Division of Nephrology   (Germany)

^d Westpfalz Klinikum GmbH   (Germany)

^e LUDWIG MAXIMILIANS UNIVERSITY   (Germany)

Author keywords

casecontrol study; glomerular filtration rate; immunosuppression; infectious complication; renal function

Indexed keywords

CORTICOSTEROID; CYCLOSPORIN A; CYTOKINE RECEPTOR ANTAGONIST; INTERLEUKIN 2 RECEPTOR BLOCKING AGENT; LYMPHOCYTE ANTIBODY; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; RITUXIMAB; TACROLIMUS; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AGED; ARTICLE; CONTROLLED STUDY; FEMALE; FUNGAL EXAMINATION; GLOMERULUS FILTRATION RATE; GRAFT RECIPIENT; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; INFECTION PREVENTION; INFECTION RISK; INTENSIVE CARE; KIDNEY BIOPSY; KIDNEY DYSFUNCTION; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RISK ASSESSMENT; TREATMENT RESPONSE;

CASE-CONTROL STUDIES; DISEASE OUTBREAKS; FEMALE; FOLLOW-UP STUDIES; GLOMERULAR FILTRATION RATE; HUMANS; KIDNEY FAILURE, CHRONIC; KIDNEY FUNCTION TESTS; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; PNEUMOCYSTIS INFECTIONS; PNEUMOCYSTIS JIROVECII; PROGNOSIS; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 79958134312     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfq689     Document Type: Article

References (19)

1. Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357: 2601-2614. (Pubitemid 350294226)
2. Martin SI, Fishman JA. Pneumocystis pneumonia in solid organ transplant recipients. Am J Transplant 2009; 9: S227-S233.
3. European best practice guidelines for renal transplantation. Section IV: long-term management of the transplant recipient. Nephrol Dial Transplant 2002; 17: 1-67.
4. Kasiske BL, Zeier MG, Chapman JR et al. KDIGO clinical practice guideline for the care of kidney transplant recipients: a summary. Kidney Int 2010; 77: 299-311.
5. Batiuk TD, Bodziak KA, Goldman M. Infectious disease prophylaxis in renal transplant patients: a survey of US transplant centers. Clin Transplant 2002; 16: 1-8. (Pubitemid 34555482)
6. Schmoldt S, Schuhegger R, Wendler T et al. Molecular evidence of nosocomial Pneumocystis jirovecii transmission among 16 patients after kidney transplantation. J Clin Microbiol 2008; 46: 966-971. (Pubitemid 351379988)
7. de Boer MG, Bruijnesteijn van Coppenraet LE, Gaasbeek A et al. An outbreak of Pneumocystis jiroveci pneumonia with 1 predominant genotype among renal transplant recipients: interhuman transmission or a common environmental source? Clin Infect Dis 2007; 44: 1143-1149. (Pubitemid 46651235)
8. Yazaki H, Goto N, Uchida K et al. Outbreak of Pneumocystis jiroveci pneumonia in renal transplant recipients: P. jiroveci is contagious to the susceptible host. Transplantation 2009; 88: 380-385.
9. Arichi N, Kishikawa H, Mitsui Y et al. Cluster outbreak of Pneumocystis pneumonia among kidney transplant patients within a single center. Transplant Proc 2009; 41: 170-172.
10. Radisic M, Lattes R, Chapman JF et al. Risk factors for Pneumocystis carinii pneumonia in kidney transplant recipients: a case-control study. Transpl Infect Dis 2003; 5: 84-93. (Pubitemid 37221472)
11. Neff RT, Jindal RM, Yoo DY et al. Analysis of USRDS: incidence and risk factors for Pneumocystis jiroveci pneumonia. Transplantation 2009; 88: 135-141.
12. Lufft V, Kliem V, Behrend M et al. Incidence of Pneumocystis carinii pneumonia after renal transplantation. Impact of immunosuppression. Transplantation 1996; 62: 421-423. (Pubitemid 26277354)
13. Oz HS, Hughes WT. Novel anti-Pneumocystis carinii effects of the immunosuppressant mycophenolate mofetil in contrast to provocative effects of tacrolimus, sirolimus, and dexamethasone. J Infect Dis 1997; 175: 901-904. (Pubitemid 27142965)
14. Ritter ML, Pirofski L. Mycophenolate mofetil: effects on cellular immune subsets, infectious complications, and antimicrobial activity. Transpl Infect Dis 2009; 11: 290-297.
15. Arend SM, Westendorp RG, Kroon FP et al. Rejection treatment and cytomegalovirus infection as risk factors for Pneumocystis carinii pneumonia in renal transplant recipients. Clin Infect Dis 1996; 22: 920-925. (Pubitemid 26260589)
16. Kuypers DR,VanrenterghemY, Squifflet JP et al. Twelve-month evaluation of the clinical pharmacokinetics of total and free mycophenolic acid and its glucuronide metabolites in renal allograft recipients on low dose tacrolimus in combination with mycophenolate mofetil. Ther Drug Monit 2003; 25: 609-622. (Pubitemid 37238896)
17. Weber LT, Shipkova M, Armstrong VW et al. The pharmacokineticpharmacodynamic relationship for total and free mycophenolic acid in pediatric renal transplant recipients: a report of the German study group on mycophenolate mofetil therapy. J Am Soc Nephrol 2002; 13: 759-768. (Pubitemid 34183943)
18. Bergrem H, Jervell J, Flatmark A. Prednisolone pharmacokinetics in cushingoid and non-cushingoid kidney transplant patients. Kidney Int 1985; 27: 459-464. (Pubitemid 15142701)
19. Lv J, Zhang H, Cui Z et al. Delayed severe pneumonia in mycophenolate mofetil-treated patients with IgA nephropathy. Nephrol Dial Transplant 2008; 23: 2868-2872